EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces

Davide Barbagallo iD, Donatella Ponti, Barbara Bassani iD, Antonino Bruno iD, Laura Pulze, Shreya A Akkihal iD, Jonahunnatha N George-William iD, Rohit Gundamaraju iD, Paola Campomenosi iD

International Journal of Molecular Sciences · 26.07.2024 · 25 (15) · 8191

DOI: 10.3390/ijms25158191 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.07.2024. Verfasst von Davide Barbagallo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics "Giovanni Sichel", University of Catania, Via Santa Sofia 89,…. Hauptthemen laut MEDLINE: MicroRNAs, Drug Resistance, Neoplasm, Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, Italian Ministry of University and Research PRIN 2022, Italian Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MicroRNAs (miRNAs) are mighty post-transcriptional regulators in cell physiology and pathophysiology. In this review, we focus on the role of miR-223-3p (henceforth miR-223) in various cancer types. MiR-223 has established roles in hematopoiesis, inflammation, and most cancers, where it can act as either an oncogenic or oncosuppressive miRNA, depending on specific molecular landscapes. MiR-223 has also been linked to either the sensitivity or resistance of cancer cells to treatments in a context-dependent way. Through this detailed review, we highlight that for some cancers (i.e., breast, non-small cell lung carcinoma, and glioblastoma), the oncosuppressive role of miR-223 is consistently reported in the literature, while for others (i.e., colorectal, ovarian, and pancreatic cancers, and acute lymphocytic leukemia), an oncogenic role prevails. In prostate cancer and other hematological malignancies, although an oncosuppressive role is frequently described, there is less of a consensus. Intriguingly, NLRP3 and FBXW7 are consistently identified as miR-223 targets when the miRNA acts as an oncosuppressor or an oncogene, respectively, in different cancers. Our review also describes that miR-223 was increased in biological fluids or their extracellular vesicles in most of the cancers analyzed, as compared to healthy or lower-risk conditions, confirming the potential application of this miRNA as a diagnostic and prognostic biomarker in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsDrug Resistance, NeoplasmNeoplasmsGene Expression Regulation, NeoplasticHumansAnimals

Stichwörter der Autor:innen

biomarkercancercancer immunitychemoresistancediagnosisinflammationmiR-223-3pmicroRNAprognosisradioresistance

Substanzen

MicroRNAsMIR223, human

Autor:innen und Institutionen

  • Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics "Giovanni Sichel", University of Catania, Via Santa Sofia 89, 95123 Catania, Italy.
  • Interdisciplinary Research Centre on the Diagnosis and Therapy of Brain Tumors, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy.
  • Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Corso della Repubblica 79, 04100 Latina, Italy.
  • Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via Fantoli 16/15, 20138 Milano, Italy.
  • Department of Biotechnology and Life Sciences, DBSV, University of Insubria, Via J.H. Dunant 3, 21100 Varese, Italy.
  • Independent Researcher, 35004 SE Swenson St, Snoqualmie, WA 98065, USA.

ORCID-Profile: Davide Barbagallo, Barbara Bassani, Antonino Bruno, Shreya A Akkihal, Jonahunnatha N George-William, Rohit Gundamaraju, Paola Campomenosi

Förderung

  • Italian Ministry of University and Research
  • Italian Ministry of University and Research PRIN 2022
  • Italian Association for Cancer Research
  • Ricerca Corrente IRCCS Multi Medica

Zitieren

APA

Barbagallo, D., Ponti, D., Bassani, B., Bruno, A., Pulze, L., Akkihal, S. A., George-William, J. N., Gundamaraju, R., & Campomenosi, P. (2024). MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces. International Journal of Molecular Sciences, 25(15), 8191. https://doi.org/10.3390/ijms25158191

Vancouver

Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal SA, et al. MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces. International Journal of Molecular Sciences. 2024;25(15):8191. doi:10.3390/ijms25158191

BibTeX
@article{Barbagallo2024,
  author = {Barbagallo, Davide and Ponti, Donatella and Bassani, Barbara and Bruno, Antonino and Pulze, Laura and Akkihal, Shreya A and George-William, Jonahunnatha N and Gundamaraju, Rohit and Campomenosi, Paola},
  title = {MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8191},
  doi = {10.3390/ijms25158191}
}
Kostenlos starten →